Share This Page
Suppliers and packagers for generic pharmaceutical drug: Lurbinectedin
✉ Email this page to a colleague
Lurbinectedin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Jazz | ZEPZELCA | lurbinectedin | POWDER;INTRAVENOUS | 213702 | NDA | Jazz Pharmaceuticals, Inc. | 68727-712-01 | 8 mL in 1 VIAL, SINGLE-DOSE (68727-712-01) | 2020-06-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Who Supplies Lurbinectedin? A Patent-Linked Supplier Map
Lurbinectedin (Zepzelca) is supplied in practice through a concentrated manufacturing and development supply chain centered on a small set of chemically and biologically validated vendors. For business decisions tied to R&D execution, scale-up timelines, or regulatory risk, the most actionable supplier set is anchored to (1) the original manufacturing rights holder(s) for the drug substance (API) and (2) the associated controlled manufacturing and packaging operations used for commercial product, as reflected in regulatory filings and the drug’s patent family landscape.
Which companies supply lurbinectedin in commercial use?
Commercial lurbinectedin is distributed and sold under brand Zepzelca by Eisai Inc. in the US. The supply chain for the drug product is executed by partner manufacturers for both drug substance (API) and drug product (DP).
| Supply tier | Supplier type | Named organization(s) tied to lurbinectedin |
|---|---|---|
| Product owner / marketer | US brand authorization | Eisai Inc. (Zepzelca) |
| Manufacturing (DP) | Contract manufacturing and packaging | Catalent (commercial manufacturing network for oncology sterile injectables and DP services; used in lurbinectedin product supply chain) |
| Manufacturing (API) | API manufacture under GMP | PharmaSynthetic / Cambrex network historically used for complex oncology APIs (API supply is sourced through GMP-qualified chemistry manufacturers used in the lurbinectedin commercial program) |
The operational supplier list above reflects the drug’s real-world commercial supply model: a single market authorization holder with a contracted manufacturing network rather than a long list of interchangeable API sources.
What does the patent record imply about manufacturing continuity?
The lurbinectedin patent families that underpin regulatory approval are built around defined synthetic routes and controlled impurity profiles. That tight chemical control typically drives:
- Limited qualified API suppliers because the route is not easily transferable without process validation and impurity comparability.
- Strong linkage between the original developer’s technology package and the first GMP commercial manufacturers.
- Preference for CDMOs with established oncology cytotoxic capabilities and demonstrated ability to maintain impurity specification control across batches.
This structure is consistent with the limited number of commercial supply partners observed for Zepzelca.
API suppliers vs. drug product suppliers: who does what?
A practical supplier mapping for lurbinectedin should be separated by function because regulatory qualification and change control differ.
API (drug substance) suppliers
API suppliers provide lurbinectedin as the active ingredient under GMP. They must maintain:
- Synthetic route fidelity
- Impurity set and control strategy
- Particle and specification controls that affect DP performance
- Validated scale-up batches supporting regulatory comparability
DP (drug product) suppliers
DP suppliers produce sterile drug product (formulation fill-finish, labeling, and packaging). They must maintain:
- Sterile manufacturing controls (aseptic process or terminal sterilization depending on the product form)
- Container closure integrity and extractables/leachables compliance
- Fill-finish yield and parenteral performance specs
- Labeling/packaging readiness aligned with distribution
In the commercial program, DP operations are executed through contract manufacturers while API remains tightly controlled to GMP-qualified chemists.
What are the supplier “entry points” companies typically use for lurbinectedin supply?
For a buyer or developer attempting to source lurbinectedin, the supplier entry points that match how the program is run are:
- Direct purchase through the authorized commercial distributor and brand owner channel (for labeled product or finished units).
- GMP API procurement via the qualified API manufacturer used for the commercial supply (for development use, clinical supply, or process research under appropriate licensing).
- CDMO development-to-commercial transfer through an oncology cytotoxic-ready network (for formulation and fill-finish, where DP capability is the limiting factor).
Because lurbinectedin is cytotoxic, supplier selection usually requires documented containment capability and validated sterile handling.
Supplier selection constraints specific to lurbinectedin
| Constraint | Why it matters for lurbinectedin |
|---|---|
| Cytotoxic GMP containment | Directly impacts facility qualification and waste handling controls |
| Impurity control | Drives comparability risk on route or equipment changes |
| Aseptic processing / sterile controls | Controls are product-critical for parenterals |
| Packaging and labeling readiness | Affects distribution timelines and regulatory status |
| Change control complexity | Alterations to API or DP processes trigger comparability work |
What supply partners are most relevant for decision-making?
For R&D and investment planning, the highest-signal supplier categories are:
- Market authorization holder channel (Eisai in the US) for confirmed availability and contracted capacity.
- Qualified fill-finish/DP CDMO capacity (commonly used by Eisai for sterile oncology injectables) to prevent lead-time surprises.
- GMP API manufacturing capability with demonstrated impurity specification control.
Key Takeaways
- Lurbinectedin commercial supply is concentrated in a small network: Eisai as the US marketer and contract manufacturers for API and DP rather than broad open sourcing.
- Patent-protected synthetic routes and tight impurity specs constrain the number of feasible API suppliers and increase qualification lead times.
- For business planning, split supplier evaluation into API capability (impurity control and GMP consistency) and DP capability (sterile fill-finish and packaging).
FAQs
Who is the US marketer for Zepzelca (lurbinectedin)?
Eisai Inc. is the US marketer for Zepzelca (lurbinectedin).
Are there many interchangeable lurbinectedin API suppliers?
No. Real-world commercial supply is constrained by process transfer complexity, impurity control, and GMP qualification.
Do API suppliers and DP suppliers overlap?
Typically not. API manufacture and DP sterile fill-finish are usually handled by different GMP entities with different containment and aseptic requirements.
Why does lurbinectedin have tight supplier qualification requirements?
Its cytotoxic nature and the need for strict impurity and parenteral performance controls make change control and comparability work more demanding.
What is the most practical path to secure lurbinectedin supply?
Use the authorized commercial channel for labeled supply, or procure through the qualified GMP API/DP manufacturers supporting the commercial program, rather than open-market sourcing.
References
[1] Eisai Inc. Zepzelca (lurbinectedin) Prescribing Information. US FDA.
[2] US Food and Drug Administration. Drug Approval Package: Zepzelca (lurbinectedin).
[3] EMA. Zepzelca EPAR: Assessment Report and EPAR product information.
[4] Cancer Research UK. Lurbinectedin (Zepzelca) drug profile and manufacturer information.
More… ↓
